Skip to product information
Adaro Deca 250
  • Adaro Deca 250
  • Adaro Deca 250
Adaro Deca 250

Adaro Deca 250

Rs. 100.00
Product Details

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone structurally similar to luteinizing hormone (LH). It binds to LH/hCG receptors in gonadal tissues, stimulating steroidogenesis and gametogenesis. Due to its ability to mimic endogenous LH, hCG plays a crucial role in reproductive endocrinology and is widely used in both male and female infertility management.


Indications & Mechanism of Action

AdaroHCG 5000 is indicated for:

In Females:

  1. Ovulation Induction: Used in anovulatory or oligo-ovulatory women (e.g., polycystic ovarian syndrome) in combination with other fertility drugs (clomiphene, menotropins).
  2. Assisted Reproductive Technologies (ART): Triggers final follicular maturation and ovulation in IVF, IUI, or other ART protocols.

In Males:

  1. Hypogonadotropic Hypogonadism: Stimulates Leydig cells in the testes to secrete testosterone, aiding spermatogenesis.
  2. Cryptorchidism (Prepubertal Boys): Facilitates testicular descent in selected patients without anatomical obstruction.

Pharmacodynamics:

  • Activates LH/hCG receptors → stimulates gonadal steroid hormone secretion.
  • In women: promotes corpus luteum maintenance and progesterone secretion.
  • In men: enhances intratesticular testosterone, essential for sperm production and testicular development.
  • Plays a therapeutic role in restoring fertility in hypogonadal and anovulatory conditions.
Clinical& Safety

Contraindications:
• Known hypersensitivity to hCG or excipients.
• Presence of hormone-sensitive tumors (ovarian, testicular, prostatic carcinoma).
• Primary ovarian failure (in females) or primary testicular failure (in males).
• Pregnancy, except when used in ART protocols.
• Active thromboembolic disorders.
Potential Drug Interactions:
• Concurrent use with fertility drugs (FSH, menotropins) increases risk of ovarian hyperstimulation syndrome (OHSS).
• May alter response to anticoagulants.
• Interference possible with exogenous androgen therapy in men.
Adverse Reactions:
• Females: OHSS, multiple pregnancies, abdominal pain, ovarian cysts.
• Males: Gynecomastia, water retention, premature epiphyseal closure (in adolescents).
• General: Injection site pain, headache, irritability, mood swings.
Dosage & Administration:
• Females: 5,000–10,000 IU IM or SC as a single dose following ovarian stimulation therapy.
• Males: 1,000–4,000 IU IM or SC two to three times weekly, based on clinical indication and physician discretion.
• Cryptorchidism (Boys): 500–1,500 IU IM or SC 2–3 times weekly for several weeks.
• Reconstitute lyophilized powder with provided diluent prior to use.
• Not for intravenous administration.
Warnings & Precautions

1. Ovarian Hyperstimulation Syndrome (OHSS): Monitor ovarian size and estradiol levels to minimize risk.
2. Multiple Gestations: Increased probability in ART cycles; appropriate counseling required.
3. Thromboembolic Events: Use cautiously in patients with cardiovascular risk factors.
4. Pediatric Use: Prolonged administration in boys can induce premature epiphyseal closure; monitor growth.
5. Endocrine Monitoring: Regular hormone panels, semen analysis (in men), and ultrasound (in women) recommended.
Storage & Handling

• Store lyophilized powder at 2–8°C.
• Protect from light.
• Once reconstituted, use immediately or within 24 hours if refrigerated.
• Do not freeze after reconstitution.
Ethical& Regulatory

• Prescription-only medicine; not indicated for weight loss, bodybuilding, or performance enhancement.
• Controlled under WADA anti-doping regulations.
• Manufactured under GMP, FDA, and EMA guidelines to ensure product integrity.

Related items